NCT03536598View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia

PHASE3CompletedINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

October 14, 2016

Primary Completion Date

September 4, 2017

Study Completion Date

September 4, 2017

Conditions
Hypertension With Hyperlipidemia
Interventions
DRUG

Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg

DRUG

Amlodipine 10 mg + Valsartan 160 mg

DRUG

Valsartan 160 mg + Rosuvastatin 20 mg

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY

NCT03536598 - Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia | Biotech Hunter | Biotech Hunter